Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma.

Abstract

A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.

• Authors: K Hahn, J F Magrina, B J Masterson
• Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Int J Gynaecol Obstet) Vol. 23 Issue 6 Pg. 509-13 (Dec 1985) ISSN: 0020-7292 [Print] United States
• PMID: 2868947 (Publication Type: Journal Article)

Chemical References

• Cyclophosphamide
• Cisplatin

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma (drug therapy, mortality, surgery)
• Cisplatin (administration & dosage)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy, mortality, surgery)
• Postoperative Care
• Prognosis
• Reoperation
• Time Factors